Balchem Co. (NASDAQ:BCPC) VP David F. Ludwig Sells 12,750 Shares

Balchem Co. (NASDAQ:BCPC) VP David F. Ludwig sold 12,750 shares of Balchem stock in a transaction on Friday, August 30th. The shares were sold at an average price of $90.00, for a total value of $1,147,500.00. Following the transaction, the vice president now directly owns 21,038 shares of the company’s stock, valued at $1,893,420. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

NASDAQ:BCPC traded up $0.49 during trading hours on Friday, hitting $104.98. The company’s stock had a trading volume of 2,365 shares, compared to its average volume of 108,581. The stock has a fifty day simple moving average of $91.67 and a 200-day simple moving average of $94.91. The company has a market capitalization of $3.38 billion, a P/E ratio of 35.18 and a beta of 1.17. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.73 and a quick ratio of 2.63. Balchem Co. has a twelve month low of $73.16 and a twelve month high of $117.79.

Balchem (NASDAQ:BCPC) last posted its earnings results on Thursday, August 1st. The basic materials company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.69 by $0.08. The firm had revenue of $161.60 million during the quarter, compared to the consensus estimate of $163.14 million. Balchem had a return on equity of 13.87% and a net margin of 12.27%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period last year, the company earned $0.76 earnings per share. On average, equities analysts predict that Balchem Co. will post 2.96 EPS for the current fiscal year.

A number of equities analysts have weighed in on BCPC shares. HC Wainwright reaffirmed a “buy” rating and set a $95.00 price target (down previously from $110.00) on shares of Balchem in a research report on Monday, August 5th. BidaskClub raised Balchem from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Zacks Investment Research cut Balchem from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $108.75.

Several institutional investors and hedge funds have recently modified their holdings of BCPC. CWM LLC bought a new position in shares of Balchem during the second quarter worth about $31,000. Krane Funds Advisors LLC purchased a new position in shares of Balchem during the second quarter valued at approximately $60,000. Tower Research Capital LLC TRC purchased a new position in shares of Balchem during the second quarter valued at approximately $65,000. Parallel Advisors LLC purchased a new position in shares of Balchem during the first quarter valued at approximately $81,000. Finally, Clarus Wealth Advisors purchased a new position in shares of Balchem during the second quarter valued at approximately $104,000. Institutional investors own 86.43% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Further Reading: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.